Litigation Details for SUN PHARMACEUTICAL INDUSTRIES LIMITED v. NOVARTIS PHARMACEUTICALS CORP. (D.N.J. 2019)
✉ Email this page to a colleague
SUN PHARMACEUTICAL INDUSTRIES LIMITED v. NOVARTIS PHARMACEUTICALS CORP. (D.N.J. 2019)
Docket | ⤷ Sign Up | Date Filed | 2019-01-09 |
Court | District Court, D. New Jersey | Date Terminated | 2019-04-04 |
Cause | 28:1331 Federal Question-Injunctive & Declaratory Relief | Assigned To | Stanley R. Chesler |
Jury Demand | None | Referred To | Cathy L. Waldor |
Patents | 6,465,504; 9,283,209 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in SUN PHARMACEUTICAL INDUSTRIES LIMITED v. NOVARTIS PHARMACEUTICALS CORP.
Details for SUN PHARMACEUTICAL INDUSTRIES LIMITED v. NOVARTIS PHARMACEUTICALS CORP. (D.N.J. 2019)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
0000-00-00 | External link to document | |||
2019-01-08 | 1 | caused two patents to be listed in FDA’s Orange Book as covering Jadenu®: U.S. Patent No. 6,465,504 (“the …declaratory relief that Novartis’ U.S. Patent No. 9,283,209 (“the ‘209 patent”) is invalid, unenforceable and…action regarding allegations of patent infringement arising under the patent laws of the United States, Title…certifications for each patent listed in the Orange Book for the RLD: (i) there are no patents listed in the Orange… Orange Book; ii) any listed patent has expired; (iii) the patent will have expired before the generic | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |